Tirofiban hydrochloride sodium chloride injection combined with cardiovascular intervention in the treatment of Acute Myocardial Infarction.

To investigate the therapeutic effect of tirofiban hydrochloride sodium chloride injection combined with cardiovascular intervention on acute myocardial infarction. Eighty-four patients with acute myocardial infarction who were treated in our hospital from April 2017 to May 2018 were divided into a control group and a treatment group using random number table method; there were 42 patients in each group. Both groups were given conventional treatment and were treated with aspirin and clopidogrel before and after operation. Moreover, the control group was treated with cardiovascular interventional therapy, while the treatment group was treated with tirofiban hydrochloride on the basis of cardiovascular interventional therapy. The patients were followed up to observe and compare the treatment condition and adverse reactions of the two groups. After percutaneous coronary intervention, the normal rate of myocardial perfusion in the treatment group was 92.86%, which was higher than 69.05% in the control group (P<0.05). After PCI, there were significant differences of thrombolysis in myocardial infarction (TIMI) flow Grade- 2 and 3 between the two groups (P<0.05). The improvement of platelet activation function in the treatment group was better than that in the control group (P<0.05). The incidence of adverse cardiac events in the treatment group was significantly lower than that in the control group (P<0.05). Tirofiban hydrochloride sodium chloride injection combined with cardiovascular intervention has a significant clinical effect in the treatment of acute myocardial infarction. It can effectively improve the blood perfusion and reduce the incidence of adverse cardiac events, suggesting a good effect on the prognosis of patients and high application value.